Compare · DMRA vs NVO
DMRA vs NVO
Side-by-side comparison of Damora Therapeutics Inc. (DMRA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DMRA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, DMRA is up 830.1% and NVO is down 34.2% - DMRA leads by 864.3 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 2 for DMRA).
- NVO has more recent analyst coverage (25 ratings vs 2 for DMRA).
- Company
- Damora Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $24.74-1.90%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- -0.34%
- +13.32%
- 1Y return
- +830.08%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 2
- 5
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DMRA
- RBC Capital Mkts initiated coverage on Damora Therapeutics with a new price target
- Damora Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- SEC Form 4 filed by Jarrett Jennifer
- SEC Form 3 filed by new insider Jarrett Jennifer
- Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 4 filed by Winslow Garrett
- SEC Form 4 filed by Turtle Cameron
- SEC Form 4 filed by Landsittel Michael
- SEC Form 4 filed by Fairmount Funds Management Llc
- SEC Form 4 filed by Cain Christopher W.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S